The data from GoodRx showed patients are having increased difficulty navigating insurance hurdles, including increased costs and more restrictions on covered drugs.
The cost of prescription drugs in the U.S. has risen 37% in the last decade, pushing past the rate of inflation and leaving Americans struggling to afford their medications, newly released tracking data shows.
This year's tally from GoodRx's data does show a slowing of the medication price spikes seen since 2014, with the highest being a rise of 39% in early 2023. But the drug savings company says the impact is lasting, and many Americans are increasingly being caught in a"Big Pinch." GoodRx describes this phenomenon as the current reality facing most Americans, who are shouldering more of their drug costs as insurance companies cover fewer prescriptions — including in Medicare plans — and add restrictions to routine drugs that once were included in their policies. Before 2010, the GoodRx data shows more than 70% of medications were covered by insurance and about 25% were restricted in some way. Now the two are almost in parity, with medications covered at 54% and medications with restrictions at 50% in 2024. And with less coverage comes higher out-of-pocket costs. On average, GoodRx found Americans spend $16.26 out-of-pocket per prescription. 24% of people are spending more than $50 monthly and 10% are spending more than $100.These cost burdens are forcing Americans to choose between leaving their prescriptions unfilled or forking out the extra dollars to get their medications. GoodRx's data shows 32% of Americans, or roughly 51 million people, have left prescriptions at the pharmacy because they were too expensive. In addition to fewer covered medications and larger restrictions on covered drugs, GoodRx says patients are also seeing higher copays, coinsurance and deductibles. For just deductibles, GoodRx says the average cost has nearly doubled, from $917 in 2014 to $1,644. "The lack of significant price decreases, coupled with poorer insurance coverage, has profound implications for patients," GoodRx writes in its report."Many people are experiencing the financial strain of paying out of pocket for their medications, especially as insurance plans cover fewer drugs and impose stricter conditions on the medications they do cover. This situation results in rising out-of-pocket costs, medication nonadherence, delayed care, poor health and inequitable access to healthcare." GoodRx said its findings show the continued efforts from lawmakers and pharmaceutical manufacturers to reduce medication barriers haven't been enough.The same day the company released its data, the U.S. Department of Health and Human Services announced lower prices on 64 drugs for some Medicare beneficiaries. The agency said the move was made possible under President Biden's Inflation Reduction Plan, which requires drugmakers to pay rebates to Medicare if their prices for certain drugs increases faster than the rate of inflation.
Please follow us on Google to support us United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Music Industry 40 Under 40: Execs & Power Players 202440 Under 40 in the music industry: Billboard's 2024 list of executives and power players revealed.
Read more »
FTSE 100, DAX 40 and CAC 40 try to Stabilize Following Thursday’s Sharp LossesOutlook on FTSE 100, DAX 40 and CAC 40 as large outflows continue to weigh on these major indices
Read more »
FTSE 100, DAX 40 and CAC 40 try to stabilize following last week’s sharp lossesOutlook on FTSE 100, DAX 40 and CAC 40 following last week’s large outflows.
Read more »
FTSE 100, DAX 40 and CAC 40 remain side-lined as US is shut for JuneteenthOutlook on FTSE 100, DAX 40 and CAC 40 amid low volume trading ahead of Thursday’s BoE meeting.
Read more »
France 40 IG Client Sentiment: Our data shows traders are now net-short France 40 for the first time since Jun 13, 2024 11:00 GMT when France 40 traded near 7,716.10.Traders are further net-short than yesterday and last week, and the combination of current sentiment and recent changes gives us a stronger France 40-bullish contrarian trading bias.
Read more »
FTSE 100, DAX 40 and CAC 40 Continue to Range TradeOutlook on FTSE 100, DAX 40 and CAC 40 amid quiet start to the week.
Read more »